Induction of anti-Tat neutralizing antibodies by the CyaA vector targeting dendritic cells: Influence of the insertion site and of the delivery of multicopies of the dominant Tat B-cell epitope

Vaccine

Volumn 28, Issue 42, 2010, Pages 6930-6941

  Fayolle, Catherine ^a,b   Davi, Maryline ^c   Dong, Hui ^a,b   Ritzel, Dorothea ^a,b   Le Page, Aurélie ^a,b   Knipping, Friederike ^a,b   Majlessi, Laleh ^a,b   Ladant, Daniel ^c   Leclerc, Claude ^a,b  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

^c CNRS   (France)

Author keywords

Adenylate cyclase; B cell epitope; HIV Tat; Neutralizing antibodies

Indexed keywords

ADENYLATE CYCLASE; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; TAT NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GENE CONSTRUCT; GENE DELETION; GENE INSERTION SEQUENCE; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN;

ADENYLATE CYCLASE TOXIN; AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGEN PRESENTATION; CHO CELLS; CPG ISLANDS; CRICETINAE; CRICETULUS; CYTOKINES; DENDRITIC CELLS; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; FEMALE; HIV ANTIBODIES; IMMUNITY, CELLULAR; MICE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; POLY I-C; RECOMBINANT PROTEINS; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 77956870448     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.07.059     Document Type: Article

References (44)

1. Arya S.K., Guo C., Josephs S.F., Wong-Staal F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985, 229(4708 (July 5)):69-73.
2. Goldstein G. HIV-1 Tat protein as a potential AIDS vaccine. Nat Med 1996, 2(9 (September)):960-964.
3. Cafaro A., Caputo A., Maggiorella M.T., Baroncelli S., Fracasso C., Pace M., et al. SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine. J Med Primatol 2000, 29(3-4 (August)):193-208.
4. Fanales-Belasio E., Cafaro A., Cara A., Negri D.R., Fiorelli V., Butto S., et al. HIV-1 Tat-based vaccines: from basic science to clinical trials. DNA Cell Biol 2002, 21(9 (September)):599-610.
5. Rezza G., Fiorelli V., Dorrucci M., Ciccozzi M., Tripiciano A., Scoglio A., et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 2005, 191(8 (April 15)):1321-1324.
6. Ensoli B., Fiorelli V., Ensoli F., Cafaro A., Titti F., Butto S., et al. Candidate HIV-1 Tat vaccine development: from basic science to clinical trials. AIDS 2006, 20(18 (November 28)):2245-2261.
7. Longo O., Tripiciano A., Fiorelli V., Bellino S., Scoglio A., Collacchi B., et al. Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. Vaccine 2009, 27(25-26 (May 26)):3306-3312.
8. Pauza C.D., Trivedi P., Wallace M., Ruckwardt T.J., Le Buanec H., Lu W., et al. Vaccination with tat toxoid attenuates disease in simian/HIV-challenged macaques. Proc Natl Acad Sci USA 2000, 97(7 (March 28)):3515-3519.
9. Belliard G., Hurtrel B., Moreau E., Lafont B.A., Monceaux V., Roques B., et al. Tat-neutralizing versus Tat-protecting antibodies in rhesus macaques vaccinated with Tat peptides. Vaccine 2005, 23(11 (February 3)):1399-1407.
10. Liang X., Casimiro D.R., Schleif W.A., Wang F., Davies M.E., Zhang Z.Q., et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys. J Virol 2005, 79(19 (October)):12321-12331.
11. Dadaglio G., Morel S., Bauche C., Moukrim Z., Lemonnier F.A., Van Den Eynde B.J., et al. Recombinant adenylate cyclase toxin of Bordetella pertussis induces cytotoxic T lymphocyte responses against HLA*0201-restricted melanoma epitopes. Int Immunol 2003, 15(12 (December)):1423-1430.
12. Saron M.F., Fayolle C., Sebo P., Ladant D., Ullmann A., Leclerc C. Anti-viral protection conferred by recombinant adenylate cyclase toxins from Bordetella pertussis carrying a CD8+ T cell epitope from lymphocytic choriomeningitis virus. Proc Natl Acad Sci USA 1997, 94(7 (April 1)):3314-3319.
13. Mascarell L., Fayolle C., Bauche C., Ladant D., Leclerc C. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis. J Virol 2005, 79(15 (August)):9872-9884.
14. Mascarell L., Bauche C., Fayolle C., Diop O.M., Dupuy M., Nougarede N., et al. Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in nonhuman primates. Vaccine 2006, 24(17 (April 24)):3490-3499.
15. Schlecht G., Loucka J., Najar H., Sebo P., Leclerc C. Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T cell epitopes and in vivo Th1-polarized T cell priming. J Immunol 2004, 173(10 (November 15)):6089-6097.
16. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408(6813 (December 7)):740-745.
17. Okahira S., Nishikawa F., Nishikawa S., Akazawa T., Seya T., Matsumoto M. Interferon-beta induction through toll-like receptor 3 depends on double-stranded RNA structure. DNA Cell Biol 2005, 24(10 (October)):614-623.
18. Adams M., Navabi H., Jasani B., Man S., Fiander A., Evans A.S., et al. Dendritic cell (DC) based therapy for cervical cancer: use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non-toxic double stranded RNA analogue poly [I]:poly [C(12)U] (Ampligen R). Vaccine 2003, 21(7-8 (January 30)):787-790.
19. Zaks K., Jordan M., Guth A., Sellins K., Kedl R., Izzo A., et al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J Immunol 2006, 176(12 (June 15)):7335-7345.
20. Cooper C.L., David H.L., Angel J.B., Morris M.L., Elfer S.M., Seguin I., et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005, 19:1473-1479.
21. Speiser D.E., Lienard D., Rufer N., Rubio-Godoy V., Rimoldi D., Lejeune F., et al. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 2005, 115(3 (March)):739-746.
22. Berraondo P., Nouze C., Preville X., Ladant D., Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007, 67(18 (September 15)):8847-8855.
23. Sambrook J., Fritsch E., Maniatis T. Molecular cloning: a laboratory manual 1989, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
24. Sakamoto H., Bellalou J., Sebo P., Ladant D. Bordetella pertussis adenylate cyclase toxin. Structural and functional independence of the catalytic and hemolytic activities. J Biol Chem 1992, 267(19 (July 5)):13598-13602.
25. Sebo P., Glaser P., Sakamoto H., Ullmann A. High-level synthesis of active adenylate cyclase toxin of Bordetella pertussis in a reconstructed Escherichia coli system. Gene 1991, 104(1 (July 31)):19-24.
26. Barry E.M., Weiss A.A., Ehrmann I.E., Gray M.C., Hewlett E.L., Goodwin M.S. Bordetella pertussis adenylate cyclase toxin and hemolytic activities require a second gene, cyaC, for activation. J Bacteriol 1991, 173(2 (January)):720-726.
27. Westrop G.D., Hormozi E.K., Da Costa N.A., Parton R., Coote J.G. Bordetella pertussis adenylate cyclase toxin: proCyaA and CyaC proteins synthesised separately in Escherichia coli produce active toxin in vitro. Gene 1996, 180(1-2 (November 21)):91-99.
28. Fayolle C., Ladant D., Karimova G., Ullmann A., Leclerc C. Therapy of murine tumors with recombinant Bordetella pertussis adenylate cyclase carrying a cytotoxic T cell epitope. J Immunol 1999, 162(7 (April 1)):4157-4162.
29. Bauche C., Chenal A., Knapp O., Bodenreider C., Benz R., Chaffotte A., et al. Structural and functional characterization of an essential RTX subdomain of Bordetella pertussis adenylate cyclase toxin. J Biol Chem 2006, 281(25 (June 23)):16914-16926.
30. Gmira S., Karimova G., Ladant D. Characterization of recombinant Bordetella pertussis adenylate cyclase toxins carrying passenger proteins. Res Microbiol 2001, 152(10 (December)):889-900.
31. Karimova G., Fayolle C., Gmira S., Ullmann A., Leclerc C., Ladant D. Charge-dependent translocation of Bordetella pertussis adenylate cyclase toxin into eukaryotic cells: implication for the in vivo delivery of CD8(+) T cell epitopes into antigen-presenting cells. Proc Natl Acad Sci USA 1998, 95(21 (October 13)):12532-12537.
32. Preville X., Ladant D., Timmerman B., Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res 2005, 65(2 (January 15)):641-649.
33. El-Azami-El-Idrissi M., Bauche C., Loucka J., Osicka R., Sebo P., Ladant D., et al. Interaction of Bordetella pertussis adenylate cyclase with CD11b/CD18: role of toxin acylation and identification of the main integrin interaction domain. J Biol Chem 2003, 278(40 (October 3)):38514-38521.
34. Hinkula J., Svanholm C., Schwartz S., Lundholm P., Brytting M., Engstrom G., et al. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol 1997, 71(7 (July)):5528-5539.
35. Majlessi L., Simsova M., Jarvis Z., Brodin P., Rojas M.J., Bauche C., et al. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. Infect Immun 2006, 74(4 (April)):2128-2137.
36. Marechal V., Clavel F., Heard J.M., Schwartz O. Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol 1998, 72(3 (March)):2208-2212.
37. Ladant D., Ullmann A. Bordetella pertussis adenylate cyclase: a toxin with multiple talents. Trends Microbiol 1999, 7(4 (April)):172-176.
38. Guermonprez P., Khelef N., Blouin E., Rieu P., Ricciardi-Castagnoli P., Guiso N., et al. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J Exp Med 2001, 193(9 (May 7)):1035-1044.
39. van Baalen C.A., Pontesilli O., Huisman R.C., Geretti A.M., Klein M.R., de Wolf F., et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997, 78(Pt. 8 (August)):1913-1918.
40. Maggiorella M.T., Baroncelli S., Michelini Z., Fanales-Belasio E., Moretti S., Sernicola L., et al. Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. Vaccine 2004, 22(25-26 (September 3)):3258-3269.
41. Caselli E., Betti M., Grossi M.P., Balboni P.G., Rossi C., Boarini C., et al. DNA immunization with HIV-1 tat mutated in the trans activation domain induces humoral and cellular immune responses against wild-type Tat. J Immunol 1999, 162(9 (May 1)):5631-5638.
42. Cafaro A., Caputo A., Fracasso C., Maggiorella M.T., Goletti D., Baroncelli S., et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999, 5(6 (June)):643-650.
43. Loucka J., Schlecht G., Vodolanova J., Leclerc C., Sebo P. Delivery of a MalE CD4(+)-T-cell epitope into the major histocompatibility complex class II antigen presentation pathway by Bordetella pertussis adenylate cyclase. Infect Immun 2002, 70(2 (February)):1002-1005.
44. Sette A., Moutaftsi M., Moyron-Quiroz J., McCausland M.M., Davies D.H., Johnston R.J., et al. Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. Immunity 2008, 28(6 (June)):847-858.